Soon, it was demonstrated that BETis provide effective treatment against multiple myeloma (MM), acute myeloid leukaemia (AML), Burkitt’s lymphoma and mixed-lineage leukaemia (MLL)-rearranged leukaemias [36,37,38,43]. Here, KMT2A is linked to acute myeloid leukemia.